MedTrace Logo

Effect of Sulodexide in Overt Diabetic Nephropathy

NCT00130312 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 968

Last updated 2021-03-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Sulodexide

100 mg gelcap in the morning and evening

DRUG

Placebo

1 placebo gelcap in the morning and evening

Sponsors & Collaborators

  • Collaborative Study Group (CSG)

    collaborator NETWORK

  • Keryx Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Edmund J Lewis, MD · The Collaborative Study Group, Rush University Medical Center, Chicago, IL USA

  • Robert C Atkins, M.D. · The Collaborative Study Group, Monash Medical Center, Clayton, Victoria, AUSTRALIA

  • Dick deZeeuw, M.D. · The Collaborative Study Group, University of Groningen, NETHERLANDS

  • Itamar Raz, M.D. · The Collaborative Study Group, Hadassah University, Jerusalem, ISRAEL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States
  • Australia
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130312 on ClinicalTrials.gov